Published in Circulation on February 08, 2011
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation (2012) 1.95
Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol (2013) 1.63
Acute coronary events. Circulation (2012) 1.54
ESR statement on the stepwise development of imaging biomarkers. Insights Imaging (2013) 1.51
Metabolomics and cardiovascular biomarker discovery. Clin Chem (2011) 1.36
Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev (2012) 1.29
Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation (2015) 1.25
Screening for cardiovascular disease using age alone: reflections on a paper peer-reviewed as both 'radical' and 'unsurprising'. J Med Screen (2011) 1.05
Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol (2013) 1.00
Genetics of coronary artery disease. Circulation (2013) 1.00
Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation (2014) 0.98
Chapter 12: systematic review of prognostic tests. J Gen Intern Med (2012) 0.98
Genome-wide association studies of chronic kidney disease: what have we learned? Nat Rev Nephrol (2011) 0.98
Relation between leukocyte telomere length and incident coronary heart disease events (from the 1995 Canadian Nova Scotia Health Survey). Am J Cardiol (2013) 0.96
Advances in the epidemiology of heart failure and left ventricular remodeling. Circulation (2011) 0.93
Cerebral microbleeds and the risk of mortality in the general population. Eur J Epidemiol (2013) 0.93
Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound (2014) 0.92
Molecular imaging of atherosclerosis: clinical state-of-the-art. Heart (2013) 0.90
Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem (2011) 0.89
Consolidated and emerging inflammatory markers in coronary artery disease. World J Exp Med (2015) 0.89
Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept. Asian J Androl (2015) 0.85
Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis. PLoS One (2012) 0.83
Noninvasive tests for the diagnostic evaluation of dyspnea among outpatients: the Multi-Ethnic Study of Atherosclerosis lung study. Am J Med (2014) 0.81
Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives. Hum Genet (2016) 0.80
Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J (2016) 0.79
Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation. Neth Heart J (2016) 0.77
Diagnosis: Biomarkers of cardiovascular outcomes--bonanza or bias? Nat Rev Endocrinol (2013) 0.77
Arterial Stiffness. Pulse (Basel) (2013) 0.77
Pulse wave velocity correlates with aortic atherosclerosis assessed with transesophageal echocardiography. J Hum Hypertens (2015) 0.77
Novel Methods for Pulse Wave Velocity Measurement. J Med Biol Eng (2015) 0.77
Three-dimensional printed models in congenital heart disease. Int J Cardiovasc Imaging (2016) 0.77
Oxidative stress, oxidative balance score, and hypertension among a racially diverse population. J Am Soc Hypertens (2015) 0.76
Metabolic profiling-multitude of technologies with great research potential, but (when) will translation emerge? Int J Epidemiol (2016) 0.75
A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature. PLoS One (2016) 0.75
The use of machine learning for the identification of peripheral artery disease and future mortality risk. J Vasc Surg (2016) 0.75
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med (2016) 0.75
Ageing effect on flicker-induced diameter changes in retinal microvessels of healthy individuals. Acta Ophthalmol (2015) 0.75
Improved prediction of cardiovascular events in diabetic patients: Role of quantitative ultrasonic tissue characterization. J Diabetes Investig (2013) 0.75
A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts. Circulation (2017) 0.75
Difference in carotid artery elasticity in subjects with different brachial artery kinetic of vasodilatation. J Hum Hypertens (2015) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol (1990) 28.97
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation (2007) 20.44
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med (1961) 12.08
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med (1978) 11.42
Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA (2004) 9.99
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol (2010) 9.44
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA (2010) 8.90
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation (2006) 8.18
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med (2008) 7.95
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA (2003) 7.35
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ (2002) 7.14
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
The limitations of risk factors as prognostic tools. N Engl J Med (2006) 5.90
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med (2008) 5.86
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol (2005) 5.45
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation (2009) 5.26
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arterioscler Thromb Vasc Biol (2007) 4.13
Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol (2010) 3.93
Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 3.88
Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation (2010) 3.87
Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol (2003) 3.87
Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation (2002) 3.67
Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med (2004) 3.64
Elements of danger--the case of medical imaging. N Engl J Med (2009) 3.59
C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 3.50
Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation (2005) 3.28
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med (2002) 2.99
Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care (2009) 2.96
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation (2007) 2.93
Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation (2001) 2.93
Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol (2005) 2.89
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation (2010) 2.84
Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation (2009) 2.83
Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol (2002) 2.74
Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke (2003) 2.61
The use of genomics in clinical trial design. Clin Cancer Res (2008) 2.61
Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med (2009) 2.56
Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol (2010) 2.50
C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes (2008) 2.50
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation (2003) 2.41
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med (2006) 2.32
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol (2007) 2.21
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA (2003) 2.16
The search for new cardiovascular biomarkers. Nature (2008) 2.14
Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation (2007) 1.95
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1.70
Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation (2005) 1.69
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol (2010) 1.67
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2005) 1.62